Maze Therapeutics (MAZE) Other Accumulated Expenses (2024 - 2026)

Maze Therapeutics has disclosed Other Accumulated Expenses across 3 years of filings, most recently posting $5.0 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $5.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 million (changed N/A YoY), and the FY2025 annual result was $4.3 million, up 46.73% from the prior year.
• Other Accumulated Expenses came in at $5.0 million for Q1 2026 at Maze Therapeutics, up from $4.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $5.1 million in Q3 2025 to a low of $2.9 million in Q4 2024.
• The 3-year median for Other Accumulated Expenses is $4.9 million (2025), against an average of $4.5 million.
• Peak annual rise in Other Accumulated Expenses reached 46.73% in 2025, while the deepest fall reached 46.73% in 2025.
• Maze Therapeutics' Other Accumulated Expenses stood at $2.9 million in 2024, then jumped by 46.73% to $4.3 million in 2025, then grew by 17.14% to $5.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $5.0 million (Q1 2026), $4.3 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.